Chicago, October 15-16, 2024 — At the Precision Oncology & Diagnostics, Bernadette Toner, CEO of GenomeWeb, addressed the pressing issue of healthcare inequality.
New technologies in cancer detection have revolutionized the medical field but have also inadvertently widened the gap between the rich and the poor in terms of access to medical resources. Toner emphasized the need for greater efforts and innovations to close this gap.
Dr. Mao Mao, CEO of SeekIn, pointed out that many current detection technologies rely on expensive medical equipment and pose significant challenges for medical testing personnel. In response, SeekIn has introduced OncoSeek®, a milestone in the MCED (Multi-Cancer Early Detection) category, designed to make cancer detection more accessible and affordable.
OncoSeek® offers a patient-friendly solution for the simultaneous detection of nine types of cancer using a single blood sample. Powered by artificial intelligence (AI), this test represents a significant advance in preventive medicine, being capable of early detection of more than 9 types of cancer through a simple blood collection. The introduction of OncoSeek® in Nigeria is a monumental step towards diminishing cancer-related mortality rates and alleviating the economic burden of treatment, contributing to global health equity.
About Precision Oncology & Diagnostics 2024
Precision Oncology & Diagnostics 2024, developed with guidance from the editorial team of Precision Oncology News, focused on the rapidly evolving field of precision oncology, including new diagnostic and therapeutic modalities, regulatory and reimbursement trends, and implementation challenges. PMLS Precision Oncology and Diagnostics 2024 brought together key stakeholders to discuss strategies and best practices for implementing molecularly guided cancer care. Thought leaders from pharmaceutical and biotech firms, leading cancer centers, and the research community shared real-world experiences in delivering precision oncology to patient populations.